FDA Catalysts

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Altimmune Secures Analyst Backing as Pemvidutide Advances Toward Phase 3 MASH Trial

Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.

Feb 2, 2026

Business

Mobileye Eyes 2026 as Pivotal Year Amid Analyst Backing and Strategic Shifts

Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.

Feb 2, 2026

Business

Goldman Sachs Downgrades MoonLake to Sell, Citing Trial Setback and Regulatory Hurdles

Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.

Feb 2, 2026

Business

Apis Flagship Fund Outperforms in Q4 2025, Cites Stock Picks and Strategy

The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).

Feb 2, 2026

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

Nextpower Inc. Surpasses Expectations, Fueling Analyst Optimism and Higher Price Targets

The renewable energy firm's latest quarterly results, described as a 'beat and raise,' have prompted major banks to lift their valuations, signaling strong confidence in its growth trajectory within the clean energy sector.

Feb 2, 2026

Business

Skyworks Solutions Shares Slump in Q4 as Value Strategy Underperforms Broader Market

Pzena Investment Management's Focused Value Strategy lagged behind its benchmark in Q4 2025, with semiconductor firm Skyworks Solutions cited as a key detractor. The fund's commentary highlights the challenges for value investing in a market dominated by AI and mega-cap stocks.

Feb 2, 2026

Business

Dollar General's Earnings Surge Fuels Q4 Rally, Defying Broader Market Trends

Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.

Feb 2, 2026

Business

Analysts Bullish on Monolithic Power Systems, Citing Automotive and AI Demand Surge

Oppenheimer and Wells Fargo have raised price targets for Monolithic Power Systems (MPWR), highlighting robust demand from the automotive and artificial intelligence sectors as key growth drivers ahead of the company's quarterly results.

Feb 2, 2026

Business

Edwards Lifesciences Halts JenaValve Acquisition, Doubles Down on Core Valve Technology

Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.

Feb 2, 2026

Business

Disney's Long-Term Cash Flow in Focus as Ashva Capital Weighs In

Investment firm Ashva Capital Management outlines its investment case for The Walt Disney Company in its Q4 2025 letter, highlighting the entertainment giant's enduring value proposition amid near-term market volatility.

Feb 2, 2026

Business

Brown & Brown Shares Face Headwinds as BMO Capital Trims Price Target Amid Mixed Q4 Signals

Insurance brokerage giant Brown & Brown sees a key price target cut to $81 following its fourth-quarter earnings, which revealed robust fee growth but concerns over slowing organic revenue expansion.

Feb 2, 2026

Business

BeOne Medicines Deepens InSysBio Modeling Partnership to De-Risk Oncology Pipeline

BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.

Feb 2, 2026

Business

enGene Holdings Stock Plunge Tests Major Private Equity Backers

A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.

Feb 2, 2026

Business

Beyond the Benchmark: Two S&P 500 Stocks with Momentum and One Facing Headwinds

The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.

Feb 2, 2026

Business

Crane Soars Past Q4 Estimates on Aerospace Strength, But Analysts Probe Integration Challenges

Crane Company's fourth-quarter earnings outperformed expectations, fueled by robust growth in its Aerospace & Advanced Technologies division. While management celebrated strong execution, analysts on the earnings call zeroed in on the costs and complexities of integrating recent high-profile acquisitions.

Feb 2, 2026

Business

Mizuho Bullish on Erasca, Initiates Coverage with $16 Target Amid RAS Inhibitor Progress

Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.

Feb 2, 2026

Business

ABIVAX Shares Surge on Takeover Buzz and Pipeline Progress, Despite CEO Denials

ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.

Feb 2, 2026

Business

Roth Capital Shifts Stance on Energy Fuels, Upgrades to Neutral with Higher Price Target

Roth Capital has upgraded Energy Fuels (UUUU) from 'Sell' to 'Neutral', raising its price target to $15. The move follows the uranium miner's strategic acquisition of Australian Strategic Materials, expanding its rare earths portfolio and positioning within Western critical mineral supply chains.

Feb 2, 2026